Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma
Richard F Riedel, Victoria Chua, Ania Moradkhani, Natalie Krkyan, Amir Ahari, Atsushi Osada, Sant P Chawla, Richard F Riedel, Victoria Chua, Ania Moradkhani, Natalie Krkyan, Amir Ahari, Atsushi Osada, Sant P Chawla
Abstract
Background: NC-6300 is a novel epirubicin (EPI) drug conjugated polymeric micelle developed using cutting-edge micellar nanoparticle technology. The nanoparticle epirubicin conjugates EPI to a polymer via a pH-sensitive linker which enables the selective EPI release into tumor. Tumor activity was observed in a monotherapy phase Ib trial, where two of two patients with angiosarcoma achieved a partial response. To further explore the activity of NC-6300 in angiosarcoma, an expansion cohort was undertaken.
Methods: Ten patients with angiosarcoma were enrolled in the expansion cohort. Patients were dosed using the recommended dose of 150 mg/m2 intravenously (IV) once every 3 weeks. The primary endpoint was progression-free survival.
Results: The most common adverse events (AEs) of any grade, regardless of the causal relationship with NC-6300, were neutropenia (90%), fatigue, and thrombocytopenia (60% each) and nausea (50%). The most common grades 3 and 4 AEs were neutropenia (80%), thrombocytopenia (40%), and anemia and leukopenia (20% each). The median progression-free survival (mPFS) for all subjects was 5.4 months. The mPFS was 3.8 months in subjects with prior anthracycline treatment and 8.2 months in subjects without prior anthracycline treatment.
Conclusion: NC-6300 was well tolerated, showing promising activity in angiosarcoma patients without prior anthracycline treatment. NC-6300 warrants further investigation (ClinicalTrials.gov Identifier: NCT03168061).
Keywords: NC-6300; angiosarcoma; epirubicin; metastatic; nanoparticle; soft tissue sarcoma; unresectable.
© The Author(s) 2022. Published by Oxford University Press.
Figures
References
- Penel N, Bui BN, Bay JO, et al. . Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269-5274. 10.1200/JCO.2008.17.3146.
- Nielsen OS, Dombernowsky P, Mouridsen H, et al. . High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer. 1998;78(12):1634-1639. 10.1038/bjc.1998.735.
- Park C, Kim M, Kwak Y, et al. . Real-world clinical outcomes and prognostic factors for patients with advanced angiosarcoma who received systemic treatment. Cancer Res Treat. 2021;53(4):1195-1203. 10.4143/crt.2020.1337.
- Young RJ, Natukunda A, Litière S, et al. . First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer. 2014;50(18):3178-3186. 10.1016/j.ejca.2014.10.004.
- D’Angelo SP, Munhoz RR, Kuk D, et al. . Outcomes of systemic therapy for patients with metastatic angiosarcoma. Oncology 2015;89(4):205-214. 10.1159/000381917.
Source: PubMed